Phathom Defends VOQUEZNA Exclusivity as Generic Challenge Reaches Court
BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.
/ 2 items
BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.
Raymond James initiates coverage on Phathom Pharmaceuticals with a Strong Buy rating and a $28 price target, highlighting Voquezna’s unique FDA-approved profile and strong long-term outlook.